Focused on Corneal Therapeutics
Trefoil presentations at the ARVO 2020 Virtual Meeting
Accelerated healing of corneal endothelial lesions by engineered fibroblast growth factor
Proliferation of corneal endothelial cells from dystrophic corneas in organ culture stimulated by engineered human fibroblast growth factor 1 (FGF1) deriverative TTHX1114
Trefoil is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world.
Lead candidate TTHX1114 is an engineered form of FGF-1 designed to stimulate proliferation and migration of corneal endothelial cells. It is initially being developed as an intracameral injection as the first pharmacologic treatment for back of the cornea surface disease (endothelial dystrophy), the leading cause of cornea transplantation surgeries.
Trefoil's second development program focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision.